U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C10H13N5O4
Molecular Weight 267.2413
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of ZIDOVUDINE

SMILES

CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O

InChI

InChIKey=HBOMLICNUCNMMY-XLPZGREQSA-N
InChI=1S/C10H13N5O4/c1-5-3-15(10(18)12-9(5)17)8-2-6(13-14-11)7(4-16)19-8/h3,6-8,16H,2,4H2,1H3,(H,12,17,18)/t6-,7+,8+/m0/s1

HIDE SMILES / InChI
Molecular Formula C10H13N5O4
Molecular Weight 267.2413
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 1
Optical Activity UNSPECIFIED

Approval Year

Unknown
86413
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:17:05 UTC 2023
Edited
by admin
on Sat Dec 16 16:17:05 UTC 2023
Record UNII
4B9XT59T7S
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ZIDOVUDINE
EMA EPAR   EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INN   USAN  
Official Name English
ZIDOVUDINE [EP MONOGRAPH]
Common Name English
BW-A509U
Code English
AZIDOTHYMIDINE
Systematic Name English
3'-DEOXY-3'-AZIDOTHYMIDINE
Systematic Name English
THYMIDINE, 3'-AZIDO-3'-DEOXY-
Systematic Name English
ZDV
Common Name English
ZIDOVUDINE [MI]
Common Name English
COMBIVIR COMPONENT ZIDOVUDINE
Common Name English
ZIDOVUDINE [USP-RS]
Common Name English
ZIDOVUDINE [EP IMPURITY]
Common Name English
AZT
Common Name English
ZIDOVUDINE COMPONENT OF TRIZIVIR
Brand Name English
TRIZIVIR COMPONENT ZIDOVUDINE
Brand Name English
ZIDOVUDINE [IARC]
Common Name English
ZIDOVUDINE COMPONENT OF LAMIVUDINE/ZIDOVUDINE TEVA
Brand Name English
ZIDOVUDINE COMPONENT OF COMBIVIR
Common Name English
ZIDOVUDINE [USAN]
Common Name English
ZIDOVUDINE [JAN]
Common Name English
COMPOUND S
Code English
ZIDOVUDINE [EMA EPAR]
Common Name English
ZIDOVUDINE [ORANGE BOOK]
Common Name English
ZIDOVUDINE [VANDF]
Common Name English
RETROVIR
Brand Name English
3'-AZIDO-3'-DEOXYTHYMIDINE
Systematic Name English
ZIDOVUDINE [MART.]
Common Name English
ZIDOVUDINE [USP MONOGRAPH]
Common Name English
3'-AZT
Common Name English
ZIDOVUDINE [WHO-IP]
Common Name English
3'-AZIDOTHYMIDINE
Systematic Name English
ZIDOVUDINE [HSDB]
Common Name English
zidovudine [INN]
Common Name English
BW-A-509U
Code English
NSC-602670
Code English
Zidovudine [WHO-DD]
Common Name English
ZIDOVUDINUM [WHO-IP LATIN]
Common Name English
LAMIVUDINE/ZIDOVUDINE TEVA COMPONENT ZIDOVUDINE
Brand Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS COMBIVIR (AUTHORIZED: HIV INFECTIONS)
Created by admin on Sat Dec 16 16:17:08 UTC 2023 , Edited by admin on Sat Dec 16 16:17:08 UTC 2023
FDA ORPHAN DRUG 8185
Created by admin on Sat Dec 16 16:17:08 UTC 2023 , Edited by admin on Sat Dec 16 16:17:08 UTC 2023
WHO-VATC QJ05AR04
Created by admin on Sat Dec 16 16:17:09 UTC 2023 , Edited by admin on Sat Dec 16 16:17:09 UTC 2023
WHO-ATC J05AR05
Created by admin on Sat Dec 16 16:17:08 UTC 2023 , Edited by admin on Sat Dec 16 16:17:08 UTC 2023
WHO-ATC J05AF01
Created by admin on Sat Dec 16 16:17:08 UTC 2023 , Edited by admin on Sat Dec 16 16:17:08 UTC 2023
NDF-RT N0000175462
Created by admin on Sat Dec 16 16:17:09 UTC 2023 , Edited by admin on Sat Dec 16 16:17:09 UTC 2023
WHO-VATC QJ05AR01
Created by admin on Sat Dec 16 16:17:09 UTC 2023 , Edited by admin on Sat Dec 16 16:17:09 UTC 2023
WHO-ATC J05AR04
Created by admin on Sat Dec 16 16:17:08 UTC 2023 , Edited by admin on Sat Dec 16 16:17:08 UTC 2023
NCI_THESAURUS C1557
Created by admin on Sat Dec 16 16:17:08 UTC 2023 , Edited by admin on Sat Dec 16 16:17:08 UTC 2023
NDF-RT N0000175459
Created by admin on Sat Dec 16 16:17:09 UTC 2023 , Edited by admin on Sat Dec 16 16:17:09 UTC 2023
NCI_THESAURUS C97452
Created by admin on Sat Dec 16 16:17:09 UTC 2023 , Edited by admin on Sat Dec 16 16:17:09 UTC 2023
NDF-RT N0000009947
Created by admin on Sat Dec 16 16:17:09 UTC 2023 , Edited by admin on Sat Dec 16 16:17:09 UTC 2023
NDF-RT N0000175459
Created by admin on Sat Dec 16 16:17:09 UTC 2023 , Edited by admin on Sat Dec 16 16:17:09 UTC 2023
EMA ASSESSMENT REPORTS LAMIVUDINE/ZIDOVUDINE TEVA (AUTHORIZED: HIV INFECTIONS)
Created by admin on Sat Dec 16 16:17:08 UTC 2023 , Edited by admin on Sat Dec 16 16:17:08 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 6.4.2.1
Created by admin on Sat Dec 16 16:17:09 UTC 2023 , Edited by admin on Sat Dec 16 16:17:09 UTC 2023
WHO-ATC J05AR01
Created by admin on Sat Dec 16 16:17:08 UTC 2023 , Edited by admin on Sat Dec 16 16:17:08 UTC 2023
WHO-VATC QJ05AR05
Created by admin on Sat Dec 16 16:17:09 UTC 2023 , Edited by admin on Sat Dec 16 16:17:09 UTC 2023
WHO-VATC QJ05AF01
Created by admin on Sat Dec 16 16:17:09 UTC 2023 , Edited by admin on Sat Dec 16 16:17:09 UTC 2023
LIVERTOX NBK548210
Created by admin on Sat Dec 16 16:17:08 UTC 2023 , Edited by admin on Sat Dec 16 16:17:08 UTC 2023
NDF-RT N0000175459
Created by admin on Sat Dec 16 16:17:09 UTC 2023 , Edited by admin on Sat Dec 16 16:17:09 UTC 2023
Code System Code Type Description
WHO INTERNATIONAL PHARMACOPEIA
ZIDOVUDINE
Created by admin on Sat Dec 16 16:17:09 UTC 2023 , Edited by admin on Sat Dec 16 16:17:09 UTC 2023
PRIMARY Description: A white or brownish powder. Solubility: Soluble in ethanol (~750 g/l) TS, sparingly soluble in water. Category: Antiretroviral (Nucleoside Reverse Transcriptase Inhibitor). Storage: Zidovudine should be kept in a tightly closed container, protected from light. Additional information: Zidovudine may exhibit polymorphism. Definition: Zidovudine contains not less than 97.0% and not more than 103.0% of C10H13N5O4, calculated with reference to the dried substance.
USAN
Y-51
Created by admin on Sat Dec 16 16:17:09 UTC 2023 , Edited by admin on Sat Dec 16 16:17:09 UTC 2023
PRIMARY
NCI_THESAURUS
C947
Created by admin on Sat Dec 16 16:17:09 UTC 2023 , Edited by admin on Sat Dec 16 16:17:09 UTC 2023
PRIMARY
DRUG CENTRAL
2861
Created by admin on Sat Dec 16 16:17:08 UTC 2023 , Edited by admin on Sat Dec 16 16:17:08 UTC 2023
PRIMARY
CAS
30516-87-1
Created by admin on Sat Dec 16 16:17:08 UTC 2023 , Edited by admin on Sat Dec 16 16:17:08 UTC 2023
PRIMARY
MESH
D015215
Created by admin on Sat Dec 16 16:17:08 UTC 2023 , Edited by admin on Sat Dec 16 16:17:08 UTC 2023
PRIMARY
LACTMED
Zidovudine
Created by admin on Sat Dec 16 16:17:08 UTC 2023 , Edited by admin on Sat Dec 16 16:17:08 UTC 2023
PRIMARY
RS_ITEM_NUM
1724500
Created by admin on Sat Dec 16 16:17:09 UTC 2023 , Edited by admin on Sat Dec 16 16:17:09 UTC 2023
PRIMARY
IUPHAR
4825
Created by admin on Sat Dec 16 16:17:08 UTC 2023 , Edited by admin on Sat Dec 16 16:17:08 UTC 2023
PRIMARY
FDA UNII
4B9XT59T7S
Created by admin on Sat Dec 16 16:17:08 UTC 2023 , Edited by admin on Sat Dec 16 16:17:08 UTC 2023
PRIMARY
SMS_ID
100000088002
Created by admin on Sat Dec 16 16:17:09 UTC 2023 , Edited by admin on Sat Dec 16 16:17:09 UTC 2023
PRIMARY
RXCUI
11413
Created by admin on Sat Dec 16 16:17:09 UTC 2023 , Edited by admin on Sat Dec 16 16:17:09 UTC 2023
PRIMARY RxNorm
DRUG BANK
DB00495
Created by admin on Sat Dec 16 16:17:08 UTC 2023 , Edited by admin on Sat Dec 16 16:17:08 UTC 2023
PRIMARY
EPA CompTox
DTXSID8020127
Created by admin on Sat Dec 16 16:17:08 UTC 2023 , Edited by admin on Sat Dec 16 16:17:08 UTC 2023
PRIMARY
EVMPD
SUB00153MIG
Created by admin on Sat Dec 16 16:17:08 UTC 2023 , Edited by admin on Sat Dec 16 16:17:08 UTC 2023
PRIMARY
MERCK INDEX
m11592
Created by admin on Sat Dec 16 16:17:08 UTC 2023 , Edited by admin on Sat Dec 16 16:17:08 UTC 2023
PRIMARY Merck Index
DAILYMED
4B9XT59T7S
Created by admin on Sat Dec 16 16:17:08 UTC 2023 , Edited by admin on Sat Dec 16 16:17:08 UTC 2023
PRIMARY
WIKIPEDIA
ZIDOVUDINE
Created by admin on Sat Dec 16 16:17:09 UTC 2023 , Edited by admin on Sat Dec 16 16:17:09 UTC 2023
PRIMARY
ChEMBL
CHEMBL129
Created by admin on Sat Dec 16 16:17:08 UTC 2023 , Edited by admin on Sat Dec 16 16:17:08 UTC 2023
PRIMARY
NSC
602670
Created by admin on Sat Dec 16 16:17:09 UTC 2023 , Edited by admin on Sat Dec 16 16:17:09 UTC 2023
PRIMARY
PUBCHEM
35370
Created by admin on Sat Dec 16 16:17:09 UTC 2023 , Edited by admin on Sat Dec 16 16:17:09 UTC 2023
PRIMARY
HSDB
6515
Created by admin on Sat Dec 16 16:17:08 UTC 2023 , Edited by admin on Sat Dec 16 16:17:08 UTC 2023
PRIMARY
INN
6118
Created by admin on Sat Dec 16 16:17:08 UTC 2023 , Edited by admin on Sat Dec 16 16:17:08 UTC 2023
PRIMARY
CHEBI
10110
Created by admin on Sat Dec 16 16:17:08 UTC 2023 , Edited by admin on Sat Dec 16 16:17:08 UTC 2023
PRIMARY
Related Record Type Details
OAT-2
TRANSPORTER -> SUBSTRATE
Structure of ZIDOVUDINE SODIUM
SALT/SOLVATE -> PARENT
Structure of ZIDOVUDINE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1
TARGET ORGANISM->INHIBITOR
MULTIDRUG RESISTANCE PROTEIN 1
TRANSPORTER -> SUBSTRATE
Structure of ZIDOVUDINE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
MRP-2
TRANSPORTER -> NON-SUBSTRATE
OAT-1
TRANSPORTER -> SUBSTRATE
OAT-3
TRANSPORTER -> SUBSTRATE
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 2B7
METABOLIC ENZYME -> SUBSTRATE
ABCC5
TRANSPORTER -> NON-SUBSTRATE
ATP-BINDING CASSETTE SUB-FAMILY G MEMBER 2
TRANSPORTER -> SUBSTRATE
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 POLYMERASE
TARGET -> INHIBITOR
Related Record Type Details
Structure of ZIDOVUDINE DIPHOSPHATE
METABOLITE ACTIVE -> PARENT
Structure of ZIDOVUDINE MONOPHOSPHATE
METABOLITE ACTIVE -> PARENT
AMOUNT FORMED FOLLOWING ADMINISTRATION
MINOR
Structure of ZIDOVUDINE TRIPHOSPHATE
METABOLITE ACTIVE -> PARENT
Structure of 3'-AMINO-3'-DEOXYTHYMIDINE
METABOLITE TOXIC -> PARENT
Structure of ZIDOVUDINE GLUCURONIDE
METABOLITE INACTIVE -> PARENT
Structure of ZIDOVUDINE GLUCURONIDE
METABOLITE INACTIVE -> PARENT
AMOUNT OF EXCRETED
MAJOR
Related Record Type Details
Structure of THYMINE
IMPURITY -> PARENT
The impurity peaks are eluted at the following relative retention times with reference to zidovudine (retention time about 12 to 13 minutes): impurity C (thymine) about 0.3. The test is not valid unless the resolution factor between the peaks due to zidovudine and impurity B is at least 2. In the chromatogram obtained with solution (1): - the area of any peak corresponding to impurity C, when multiplied by a correction factor of 0.6, is not greater than four times the area of the principal peak in the chromatogram obtained with solution (2) (2.0%).
Structure of 3'-(3-(3-AZIDO-2,3-DIDEOXY-.BETA.-D-ERYTHRO-PENTOFURANOSYL)-3,6-DIHYDRO-5-METHYL-2,6-DIOXO-1(2H)-PYRIMIDINYL)-3'-DEOXYTHYMIDINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of Doxribtimine
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of TRIPHENYLCARBINOL
IMPURITY -> PARENT
Structure of 3'-CHLORO-3'-DEOXYTHYMIDINE
IMPURITY -> PARENT
The impurity peaks are eluted at the following relative retention times with reference to zidovudine (retention time about 12 to 13 minutes): impurity B about 1.2. The test is not valid unless the resolution factor between the peaks due to zidovudine and impurity B is at least 2. In the chromatogram obtained with solution (1):- the area of any peak corresponding to impurity B, is not greater than twice the area of the principal peak in the chromatogram obtained with solution (2) (1.0%).
Structure of STAVUDINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (TLC)
Structure of THYMINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
Structure of 3'-CHLORO-3'-DEOXYTHYMIDINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
Structure of 3'-CHLORO-3'-DEOXYTHYMIDINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
Structure of THYMINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
Structure of METHYL TRITYL ETHER
IMPURITY -> PARENT
Structure of STAVUDINE
IMPURITY -> PARENT
The impurity peaks are eluted at the following relative retention times with reference to zidovudine (retention time about 12 to 13 minutes): impurity A (stavudine) about 0.4;. The test is not valid unless the resolution factor between the peaks due to zidovudine and impurity B is at least 2. In the chromatogram obtained with solution (1):- the area of any peak corresponding to impurity A, when multiplied by a correction factor of 0.9, is not greater than the area of the principal peak in the chromatogram obtained with solution (2) (0.5%).
Structure of 1-(2'-DEOXY-.BETA.-D-THREO-PENTOFURANOSYL)THYMINE
IMPURITY -> PARENT
Structure of TRIPHENYLCARBINOL
IMPURITY -> PARENT
Not Specified
Structure of 3'-AZIDO-3'-DEOXY-5'-O-TRITYLTHYMIDINE
IMPURITY -> PARENT
Related Record Type Details
Structure of ZIDOVUDINE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC Population
PHARMACOKINETIC
CSF/PLASMA RATIO PHARMACOKINETIC Population
PHARMACOKINETIC
Tmax PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC Population
PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC Populations
PHARMACOKINETIC
CSF/PLASMA RATIO PHARMACOKINETIC Population
PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
Route of Elimination PHARMACOKINETIC
Route of Elimination PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC Population
PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC Polpulation
PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966